A5015388641- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- S100 Proteins and Annexins
- Functional Brain Connectivity Studies
- Hematopoietic Stem Cell Transplantation
- Parathyroid Disorders and Treatments
- Software Engineering and Design Patterns
- Black Holes and Theoretical Physics
- Public Health Policies and Education
- Neurological disorders and treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Immune responses and vaccinations
- Frailty in Older Adults
- Software Engineering Research
- Neurological diseases and metabolism
- PI3K/AKT/mTOR signaling in cancer
- Sexual Assault and Victimization Studies
- Bone health and treatments
- MicroRNA in disease regulation
- T-cell and B-cell Immunology
- Parkinson's Disease Mechanisms and Treatments
- Parallel Computing and Optimization Techniques
- Advanced Malware Detection Techniques
- Biological Research and Disease Studies
- Amyotrophic Lateral Sclerosis Research
Lund University
2021-2025
Stem Cell Institute
2022
Skåne University Hospital
2022
Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison p-tau181, p-tau217 and p-tau231 measured using 10 assays to detect abnormal brain amyloid-β (Aβ) status predict future progression dementia. The study included 135 patients with baseline diagnosis mild cognitive impairment (mean age 72.4 years; 60.7% women) who were followed for an average 4.9 years. Seventy-one participants had...
Recent advances in disease-modifying treatments highlight the need for accurately identifying individuals early Alzheimer's disease (AD) stages and monitoring of treatment effects. Plasma measurements phosphorylated tau (p-tau) are a promising biomarker AD, but different assays show varying diagnostic prognostic accuracies. The objective this study was to determine clinical performance novel plasma p-tau217 (p-tau217) assay, p-tau217+Janssen, perform head-to-head comparison an established...
Abstract The diagnosis of Parkinsonian disorders is currently based on clinical criteria, which have limited sensitivity until most dopaminergic neurons are lost. Here we show that cerebrospinal fluid levels DOPA decarboxylase (DDC) (also known as aromatic l -amino acid decarboxylase) can accurately identify patients with Lewy body disease (LBD) (area under the curve (AUC) = 0.89; P FDR 2.6 × 10 −13 ) and associated worse cognitive performance ( < 0.05). We also found DDC detect...
Abstract Plasma phosphorylated-tau 217 (p-tau217) is currently the most promising biomarker for reliable detection of Alzheimer’s disease (AD) pathology. Various p-tau217 assays have been developed, but their relative performance unclear. We compared key plasma tests using cross-sectional and longitudinal measures amyloid-β (Aβ)-PET, tau-PET, cognition as outcomes, benchmarked them against cerebrospinal fluid (CSF) tests. Samples from 998 individuals (mean[range] age 68.5[20.0-92.5], 53%...
The Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case-control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in disease (AD) versus non-AD and show commutability measuring patient samples candidate certified reference materials (CRMs). Thirty-three different p-tau measured paired plasma cerebrospinal fluid (CSF) from 40 participants (25 with "AD pathology" 15 "non-AD by CSF amyloid beta [Aβ]42/Aβ40 p-tau181...
Plasma p-tau217 and tau positron emission tomography (PET) are strong prognostic biomarkers in Alzheimer's disease (AD), but their relative performance predicting future cognitive decline among cognitively unimpaired (CU) individuals is unclear. In a head-to-head comparison study including nine cohorts 1,474 individuals, we show that plasma medial temporal lobe tau-PET signal display similar associations with on global composite test (R2PET = 0.34 versus R2plasma 0.33, Pdifference 0.653)...
Abstract Background Up to now, there are no clinically available minimally invasive biomarkers accurately identify mild cognitive impairment (MCI) patients who at greater risk progress Alzheimer’s disease (AD) dementia. The recent advent of blood-based markers opens the door for more accessible biomarkers. We aimed which combinations AD related plasma and other easily assessments best predict progression dementia in with (MCI). Methods included amnestic MCI ( n = 110) followed prospectively...
BACKGROUND: Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimers disease (AD) pathology. Multiple p-tau biomarkers on several analytical platforms are poised clinical use. The Association Global Biomarker Standardisation Consortium plasma phospho-tau Round Robin study engaged assay developers in blinded case-control p-tau, aiming to learn which assays provide the largest fold-changes AD compared non-AD, have strongest relationship between and cerebrospinal fluid (CSF),...
Pre-analytical factors can cause substantial variability in the measurements of cerebrospinal fluid (CSF) and plasma biomarkers Alzheimer's disease (AD). However, their effects on performance one most promising AD biomarkers, phosphorylated tau (p-tau)217, are not known. We included 50 amyloid-β positive (Aβ+) Aβ- participants from Swedish BioFINDER-1 study. Plasma CSF p-tau217 were measured using an immunoassay developed by Lilly Research Laboratories. examined effect four handling...
Abstract INTRODUCTION We evaluated differences in p‐tau levels between Alzheimer's disease (AD), a condition with brain‐specific changes p‐tau, and amyotrophic lateral sclerosis (ALS), associated increases peripheral levels. METHODS Cerebrospinal fluid plasma from 668 participants were analyzed using immunoassays specific for the low‐molecular‐weight (LMW) tau isoforms present brain (i.e., p‐tau217 Lilly , p‐tau181 ) those that detect both LMW‐ high‐molecular‐weight (HMW) expressed nervous...
Abstract Plasma phosphorylated-tau 217 (p-tau217) is currently the most promising biomarkers for reliable detection of Alzheimer’s disease (AD) pathology. Various p-tau217 assays have been developed, but their relative performance unclear. We compared key plasma tests using cross-sectional and longitudinal measures amyloid-β (Aβ)-PET, tau-PET, cognition as outcomes, benchmarked them against cerebrospinal fluid (CSF) biomarker tests. Samples from 998 individuals (mean[range] age...
Plasma p-tau217 and Tau-PET are strong prognostic biomarkers in Alzheimer's disease (AD), but their relative performance predicting future cognitive decline among cognitively unimpaired (CU) individuals is unclear. In this head-to-head comparison study including 9 cohorts 1534 individuals, we found that plasma medial temporal lobe signal showed similar associations with on a global composite test (R
Abstract Background There is an urgent need for accurate and validated methods to measure plasma phosphorylated tau (p‐Tau) biomarkers in Alzheimer´s disease (AD). Here we compared the performance of newly developed ALZpath p‐Tau217 assay other established p‐Tau assays such as Lilly p‐Tau181. Method We included 72 participants from Arizona Study Aging Neurodegenerative Disorders cohort, where analysed antemortem collected samples with well The were relevant post‐mortem neuropathological...
Abstract Background Pre‐analytical variables can greatly influence biomarkers concentration. Till now, only two studies have examined the effects of pre‐analytical factors on plasma concentrations phosphorylated tau (p‐tau) 1,2 . Hence, in this study we investigated how affect performance one most promising Alzheimer´s Disease, p‐tau217. Method We included 50 β‐amyloid positive (Aβ + ) and Aβ − participants from Swedish BioFINDER‐1 cohort. Plasma samples were either thawed at room...
ABSTRACT Understanding how hematopoietic stem and progenitor cells (HSPCs) are regulated is of central importance for the development new therapies blood disorders cell transplantation. To date, HSPC regulation has been extensively studied in vitro animal models, but less known about mechanisms vivo humans. Here, a genome-wide association study on 13,167 individuals, we identify 9 significant 2 suggestive DNA sequence variants that influence (CD34 + ) levels human blood. The identified loci...